CD274 and non-small cell lung carcinoma: We excluded 151 patients for the following reasons: absence of PD-L1 data (n = 125), participation in a clinical trial of pembrolizumab or nivolumab (n = 22), and NSCLC with ALK rearrangement (n = 4) (Fig. 1).